

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Past SARS-CoV-2 infection as protection against re-infection, comorbidities, multimorbidity and COVID-19, AI for SARS-CoV-2 variants

Peer reviewed journals featured:

- A systematic review on past SARS-CoV-2 infection as protection against re-infection [here](#)
- Randomised clinical trial of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in COVID-19 outpatients [here](#) and associated commentary [here](#)
- A narrative review on comorbidities, multimorbidity and COVID-19 [here](#)
- Observational studies on:
 - Using haplotype-based artificial intelligence (HAI) to identify SARS-CoV-2 variants [here](#)
 - Communication via interactive simulation vs text with vaccine-hesitant adults [here](#)
 - Association of post-COVID-19 condition symptoms with employment status [here](#)
 - Hospital outcomes of community-acquired Omicron infection vs influenza [here](#)
 - Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children [here](#)
 - Breakthrough infections in cancer patients following 2-3 doses of mRNA vaccines [here](#)
 - Comirnaty (Pfizer) COVID-19 vaccine in children younger than 5 years of age [here](#)
 - First-year impacts of the NHS COVID-19 app in England and Wales [here](#)
 - Assessing the impact of one million COVID-19 deaths in America [here](#)
- Editorials on:
 - The £2bn private sector NHS COVID-19 contract [here](#) and associated commentary [here](#)
 - Antithrombotic therapy in COVID-19 patients [here](#)
 - The impact of the COVID-19 pandemic on emergency department presentations [here](#)
- Commentary on:
 - When to update COVID-19 vaccine composition [here](#)
 - Human rights and the COVID-19 pandemic [here](#)
 - Rethinking how and where care is best delivered after COVID-19 [here](#)

Letters and correspondence discussed:

- Use of convalescent plasma in the treatment of COVID-19 [here](#)
- Antibiotic receipt during outpatient visits for COVID-19 in the US [here](#)
- Balancing the medical and social needs of children during COVID-19 [here](#) and [here](#)

Pre-peer review articles featured:

- Effectiveness of a telerehabilitation intervention using Recovery APP of long COVID patients [here](#)
- Modelling high booster uptake on COVID-19 burden and healthcare costs in New York [here](#)
- Brain alterations revealed by susceptibility-weighted magnetic resonance imaging [here](#)
- Real-world effectiveness of nirmatrelvir/ritonavir on COVID-19 hospitalisation in Québec [here](#)
- Protective effect from prior Omicron infection against BA.5 subvariant symptomatic reinfection [here](#)
- Serum brain injury biomarkers in people with mild-moderate COVID-19 and long COVID [here](#)
- Early treatment, inflammation and post-COVID conditions [here](#)
- Pre-infection sleep quality and quantity associated with long-term symptoms post COVID-19 [here](#)

Guidance and reports

- The World Health Organization published its weekly COVID-19 epidemiological report [here](#)
- The UK Health Security Agency published an update on SARS-CoV-2 variants of concern and variants under investigation [here](#)
- The National Clinical Evidence Taskforce released updated recommendations and flowcharts [here](#)
- The Therapeutic Goods Administration (TGA) issued provisional approval to Moderna's COVID-19 bivalent (SPIKEVAX bivalent original/Omicron BA.4-5) booster dose vaccine [here](#)

News and blogs

- Which SARS-Cov-2 variants should be included in the FDA's proposed annual COVID-19 vaccines remains unclear [here](#)
- Long COVID linked with unemployment in new analysis [here](#)
- Most COVID-19 deaths worldwide were among older people [here](#)
- Evusheld unlikely to prevent infection with current or future variants [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the Evidence Digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).